Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 11/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884087 | 0.92 | PIK3CA (0.39) | PIK3CGPIK3CAPIK3CDPIK3CBABL1 | |
| SCHEMBL1888493 | 0.90 | PIK3CG (0.38) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1888302 | 0.89 | PIK3CA (0.35) | PIK3CGPIK3CAPIK3CDPIK3CBABL1 | |
| SCHEMBL1882772 | 0.88 | PIK3CG (0.34) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1883449 | 0.86 | PIK3CG (0.34) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1888621 | 0.85 | PIK3CG (0.34) | PIK3CGPIK3CAPIK3CDPIK3CBABL1 | |
| SCHEMBL1890711 | 0.85 | PIK3CG (0.40) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL1885039 | 0.84 | PIK3CA (0.49) | PIK3CGPIK3CAPIK3CDPIK3CBABL1 | |
| SCHEMBL1887834 | 0.82 | PIK3CG (0.35) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB | |
| SCHEMBL5737384 | 0.82 | PIK3CG (0.32) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157091-B1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG | 2011-05-05 | — | — | US | disclosed |
| CN-1816549-B | Phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG | 2010-09-29 | — | — | CN | disclosed |
| EP-2157091-A1 | Inhibitors of phosphatidylinositol 3-kinase | Novartis AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-101648949-A | inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG CH | 2010-02-17 | — | — | CN | disclosed |
| EP-1622897-B1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| CN-1816549-A | Phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | PIK3CA, PIP4K2C, PIP4K2B | PIK3CG 10/4885PIK3CA 1/4885PIK3CD 4/4885 |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | PIK3CG 8/4885PIK3CA 1/4885PIK3CD 2/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | PIK3CG 8/4885PIK3CA 1/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.